CTLA4 and metastatic melanoma: In 2011, the United States Food and Drug Administration (FDA) approved the first immune checkpoint inhibitor, ipilimumab, a monoclonal antibody targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), for the treatment of metastatic melanoma.